2Mottet N, Bellmunt J, Bolla M, et al. EAU guidelines on pros- tate cancer. Part II: Treatment of advanced, relapsing, and cas- tration-resistant prostate cancer [ J ]. Eur Urol, 2011, 59 : 572- 583. 被引量：1
3Freedland SJ, Presti JC Jr, Kane C J, et al. Do younger men have better biochemical outcomes 'after radical prostatectomy? [ J ]. Urology, 2004, 63:518-522. 被引量：1
4Herold DM, Haulon AL, Movsas B, et al. Age-related prostate cancer metastases [J]. Urology, 1998, 51: 985-990. 被引量：1
6Kok DE, van Roermund JG, Aben KK, et al. Body mass index is not a predictor of biochemical re:urrence after radical prostatecto- my in Dutch men diagnosed with prostate cancer [ J]. World J Urol, 2011, 29: 695-701. 被引量：1
7Benaim EA, Pace CM, Lain PM, et al. Nadir prostate specific antigen as a predictor of progression to androgen independent prostate cancer [J]. Urology, 2002, 59: 73-78. 被引量：1
8Huang SP, Bao BY, Wu MT, et al. Impact of prostate-specific antigen (PSA) nadir and time to PSA nadir on disease progres-sion in prostate cancer treated with androgen-deprivation therapy J]. Prostate, 2011, 71: 1189-1197. 被引量：1
9Huang SP, Bao BY, Wu MT, et al. Significant associations of prostate-specific antigen nadir and time to prostate-specific anti- gen nadir with survival in prostate cancer patients treated with an- drogen-deprivation therapy [ J]. Aging Male, 2012, 15: 34-41. 被引量：1
10Morote J, Trilla E, Esquena S, et al. Nadir prostate specific anti- gen best predicts the progression to androgen independent prostate cancer [J]. Int J Cancer, 2004, 108z 877-881. 被引量：1
